Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Abiomed

- PMLiVE

J&J gets FDA green light for myeloma drug Darzalex

First-in-classtargeted immunotherapy wins US approval

- PMLiVE

J&J files three-monthly schizophrenia drug in Europe

Hopes to gain advantage over its competitors

- PMLiVE

J&J starts to feel biosimilar competition bite

Secondquarter Remicade sales outside the US dropped 26%

- PMLiVE

AbbVie remains top of immunology sales

But the threat of biosimilars once again threatens to shake up the leader board

Energy drinks and heart disease

Say Communications analyses the link between energy drinks and heart disease and how the issue has been covered in the media.

Say Communications

- PMLiVE

Amgen starts shipping Corlaner in US

Firm also reports healthy financial growth in the first quarter

National Institute for Health and Care Excellence NICE logo

NICE backs biosimilars in rheumatoid arthritis guidance

Seven biologic drugs (DMARDs) and two biosimilars recommended

- PMLiVE

FDA approves Olysio/Sovaldi combination in hep C

Janssen drug recommended for use along with Gilead’s blockbuster

- PMLiVE

Johnson & Johnson to acquire Alios BioPharma for $1.75bn

Will gain access to the biopharma's portfolio of viral infection candidates

- PMLiVE

J&J fast-tracks Ebola vaccine

Human clinical trials set to begin in early 2015

- PMLiVE

FDA approves J&J’s diabetes combo

Invokamet combines Invokana and metformin to help reduce blood sugar

- PMLiVE

EC approves Janssen rare blood disorder drug

Sylvant available to treat multicentric Castleman's disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links